Late-stage drug companies take more than half of China’s venture capital pie
SHANGHAI – In 2013, venture capital (VC) activity in China’s life sciences sector remained strong, dipping only slightly below the year previous. Investor enthusiasm did not diminish even when China barred companies from holding initial public offerings (IPO) here, the exit of choice for VCs.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter